In another study that used publicly available datasets and bioinformatic tools, EZH2, along with five other genes, was detected as a potential prognostic and predictive biomarker for response to immune-checkpoint inhibitors treatment in patients with SCLC. This evidence concerns the gene EZH2 and small cell lung carcinoma.